Strategic Partnerships Forge Biologics has established collaborations with leading organizations such as Progeria Research Foundation, Fractyl Laboratories, and Affinia Therapeutics, demonstrating a strong demand for gene therapy manufacturing and development services across diverse research and clinical programs.

Innovative Platform Launch The recent launch of the FUEL manufacturing platform positions Forge as a forward-thinking provider, offering advanced manufacturing solutions that can serve clients seeking scalable and flexible gene therapy production capabilities.

Expanding Expertise Forge's focus on developing therapies for neuromuscular diseases and its integration within the Ajinomoto Bio-Pharma Services group highlight its expanding capabilities in specialized gene therapy manufacturing, creating opportunities to attract clients with niche therapeutic needs.

Financial Capacity With a revenue range of 100 to 250 million dollars and recent funding of 90 million dollars, Forge has significant financial resources to support large-scale manufacturing projects and long-term strategic collaborations.

Tech-Driven Solutions Utilizing a robust tech stack including cloud services, data visualization, and security platforms, Forge can offer clients innovative, reliable, and scalable manufacturing solutions, making it an attractive partner for biotech companies developing cutting-edge gene therapies.